However, in FMF patients who are resistant to colchicine, IL-1-blocking therapies, such as the recombinant IL-1 receptor antagonist anakinra or the anti–IL-1β monoclonal antibody canakinumab, have proven effective at suppressing Pyrin inflammasome–driven inflammation and achieving complete remission of febrile attacks [560, 561]. The gene discussed is IL1B; the disease is familial Mediterranean fever.